1. Soluble programmed cell death ligand 1 as a novel biomarker for nivolumab therapy for non-small-cell lung cancer;Okuma;Clin Lung Cancer,2018
2. Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors;Wei;Med,2018
3. Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer;Gong;J Exp Med,2019
4. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab;Guibert;Lung Cancer,2018
5. Monitoring PD-L1 expression on circulating tumor-associated cells in recurrent metastatic non-small-cell lung carcinoma predicts response to immunotherapy with radiation therapy;Moran;JCO Precis Oncol,2022